Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air Inc (NASDAQ: XAIR) is a clinical-stage medical technology company pioneering nitric oxide delivery systems for respiratory care. This news hub provides investors and healthcare professionals with essential updates on regulatory milestones, clinical trial progress, and technological advancements related to the LungFit™ platform.
Access timely press releases covering FDA communications, partnership announcements, and research developments in pulmonary hypertension treatment. Our curated collection includes updates on international regulatory strategies and peer-reviewed study publications, offering critical insights into the company's position within the respiratory therapy market.
Key content categories include clinical trial results, device approval updates, executive leadership changes, and scientific conference presentations. This resource enables stakeholders to track the company's progress in developing NO-based solutions for ventilator-associated pneumonia and chronic lung conditions.
Bookmark this page for streamlined access to material developments affecting XAIR's market position. For comprehensive analysis of how these updates may influence investment decisions, consult your financial advisor and review official SEC filings.
Beyond Air (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company, has announced its participation in the BTIG Virtual Biotechnology Conference 2024. The event is scheduled for August 5-6, 2024. Steve Lisi, Chairman and CEO of Beyond Air, will be available for one-on-one meetings during the conference.
Beyond Air focuses on harnessing the power of nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The company's affiliate, Beyond Cancer, is involved in cancer treatment research. Interested parties can contact their BTIG representative to schedule meetings with the Beyond Air team during the conference.
Beyond Air (NASDAQ: XAIR) reported its financial results for the fiscal fourth quarter and full year 2024, alongside a corporate update. The company appointed David Webster as Chief Commercial Officer and upgraded their LungFit PH device. The device has been utilized in over 50 hospitals, treating more than 1,100 patients. However, FY 2025 revenue guidance was revised to over $10M, down from $12M-$16M. Cost-cutting measures were implemented, reducing headcount by over 20%, and some R&D projects were paused. Net loss for FY 2024 was $60.2M, compared to $55.8M in FY 2023. The company expects to be cash flow positive by Q4 2026 and has $34.5M in cash and equivalents as of March 31, 2024. A conference call is scheduled for June 24, 4:30 PM ET.
Beyond Air, a company specializing in medical devices and biopharmaceuticals, has appointed David Webster as Chief Commercial Officer, effective July 8, 2024. Webster brings over 20 years of executive experience in the life sciences industry, including roles at Body Vision Medical and NeuroLogica. His appointment comes as Beyond Air's product, LungFit PH, is set to lead the nitric oxide (NO) market, with promising customer feedback and market engagement. The company granted Webster an inducement stock option to purchase 125,000 shares, vesting over four years. Webster's expertise is expected to drive significant market share gains for LungFit PH.
Beyond Cancer has revealed promising Phase 1a clinical data for their ultra-high concentration nitric oxide (UNO) platform, showing early tumor responses and immune system activation in subjects with relapsed or refractory unresectable solid tumors.
Data presented at the 2024 American Society of Clinical Oncology Annual Meeting highlighted immune biomarker responses, including increases in dendritic cells, cytotoxic T-cells, and central memory T-cells, along with a decrease of 54% in Myeloid Derived Suppressor Cells (MDSCs) post-treatment.
The Phase 1b trial, combining UNO with anti-PD-1 therapy, has been filed for regulatory approval and aims to enroll up to 20 subjects. UNO was generally well-tolerated, with primarily Grade 1 toxicities and one Grade 3 adverse event noted.
Beyond Air (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company, will announce its fiscal year-end 2024 financial results on June 24, 2024. The company, specializing in nitric oxide therapies for respiratory illnesses, neurological disorders, and solid tumors, will host a conference call and webcast at 4:30 pm ET on the same day. The call can be accessed domestically at 1-877-407-0784 and internationally at 1-201-689-8560 using Conference ID: 13746892. A live and replay webcast will be available on the company's website.
Beyond Cancer, has been chosen to present on the clinical development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting. The company will host an event in Chicago featuring key opinion leaders to discuss the ongoing clinical development of UNO. Additionally, presentations at the ASCO Annual Meeting will showcase new data from the Phase 1 trial evaluating UNO101 in various malignancies.
FAQ
What is the current stock price of Beyond Air (XAIR)?
What is the market cap of Beyond Air (XAIR)?
